Shares of Merus jumped after the company posted positive interim data from a trial of its treatment for head and neck cancer. The stock rose 31% to $54.49 on Friday. Shares have climbed 24% over the ...

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the ...

PDS Biotechnology Corporation (NASDAQ:PDSB) unveiled compelling new data on its Versamune HPV (PDS0101) immunotherapy at the ...

Merus N.V. (MRUS) stock surges after interim trial data from a cancer trial for the company's lead asset, petosemtamab with ...

Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development ...

Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio ® is a ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end point of progression-free survival.

PDS Biotechnology Corporation (NASDAQ: PDSB) Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...